Kidney Cancer

Overall, 76% of patients with a CD70 TPS of at least 50% achieved a reduction in tumor burden.

“Based on these data, casdatifan has the potential to be a future treatment option for kidney cancer," says Toni K. Choueiri, MD.

The RMAT designation is supported by interim data from the ongoing phase 1 TRAVERSE trial.

"The encouraging results suggest that alternating pazopanib with bevacizumab is a promising treatment regimen for renal cell carcinoma patients in the favorable risk group," says Saby George, MD, FACP.

According to the authors, "These results support the use of Benmelstobart plus anlotinib as a new first-line treatment for advanced RCC.”

On Cox regression analysis, glycoproteins were predictive of PFS response to nivolumab plus cabozantinib vs sunitinib (P < .01).

Late-breaking data from ESMO 2024 suggest ipilimumab / nivolumab may be a new standard of care for non-clear cell renal cell cancer.

“Our study highlights critical gaps in health care equity when it comes to treatments that have been shown effective in prolonging survival,” says Solomon Woldu, MD.

"Overall, we found that patients with recurrent RCC following adjuvant IO continued to have responses to different types of first-line systemic therapy," says Talal El Zarif, MD.

“The challenge now is to understand how these key aspects of mitochondrial metabolism become activated, why they stimulate metastasis, and whether we can safely block them,” says Ralph J. DeBerardinis, MD, PhD.

"We can individualize the access and the way we do the operation based on the patient's characteristics, and that hasn't happened in a very long time," says Ketan K. Badani, MD.

The grants will support research evaluating ATAD2 in advanced prostate cancer and 6MP in hereditary leiomyomatosis and renal cell cancer.

"While the addition of an ICI to low dose FOTIVDA did not improve PFS outcomes after prior ICI, we consider the control arm data an important, evidence-based and clinically meaningful contribution to the oncology community treating relapsed or refractory advanced RCC following front-line ICI combinations," says Michael P. Bailey.

“These findings provide a plausible mechanism for the enhanced clinical outcome with CBM588 now seen across 2 small, randomized trials,” write the authors.

This announcement comes on the heels of an FDA acceptance of an investigational new drug application for ADI-270 in June.

CBM588 could be exciting in cancer treatment because of its potential to enhance the efficacy of immune checkpoint inhibitor-based treatment, improve patient outcomes, and modulate the gut microbiota in beneficial ways,” says Sumanta Pal, MD.

"The addition of efficacy data from the KEYNOTE-B61 trial reinforces the important role of KEYTRUDA plus LENVIMA as a frontline treatment option for adult patients with advanced RCC regardless of histology," says Takashi Owa, PhD.

A phase 1 trial of ADI-270 in clear cell RCC is expected to launch in the second half of 2024.

"The positive trends emerging from the ongoing phase 1 trial of BMC128, particularly in combination with nivolumab, underscore the transformative potential of microbiome-based therapeutics in oncology,” says Gal Markel, MD, PhD, MBA.

"There’s potentially a role here for patients with small renal masses that may not want to proceed with a minimally invasive laparoscopic or robotic procedure," says Arun Rai, MD, MBA, MSc.

"I think [these are] important data to [give to] your patients," says Laura Bukavina, MD, MPH.

Among the 3 CD70-positive patients, the ORR was 66.7%, with 2 patients achieving a partial response.

"Our first question is, in patients who were on the GLP1R agonists for a prolonged period of time, were those patients at increased or decreased risk of developing the most common GU malignancies?" says Laura Bukavina, MD, MPH.

The first-in-human study expects to begin dosing patients with DF9001 in combination with pembrolizumab in Q4 of 2024.

The dose escalation/dose expansion study is evaluating the safety and efficacy of AB-2100 in patients with ccRCC who either came back or did not improve following prior treatment with a checkpoint inhibitor and a VEGF inhibitor.

“What we need is continued work on integrating surgery and systemic therapy,” says Patrick Kenney, MD.

“This clinical study has the potential to demonstrate the value of Chimeric Antigen Receptor (CAR) T cell therapy in solid cancers such as kidney cancer with a high unmet medical need,” said Abla Creasey, PhD.

“ARO-HIF2’s ability to target cancer cells, disrupting a key tumor-driving mechanism, illustrates the potential of siRNA technology in oncology,” says James Brugarolas, MD, PhD.

“This is the first study to show a statistically significant and clinically meaningful survival improvement with any adjuvant therapy in kidney cancer, and this further supports adjuvant pembrolizumab as a standard of care after surgery in this disease setting,” says Toni K. Choueiri, MD.

The approval is based on findings from the phase 3 RENOTORCH trial, which showed that toripalimab plus axitinib prolonged progression-free survival and improved the objective response rate in patients with advanced RCC compared with sunitinib.